Skip to main content
An official website of the United States government

anti-NKG2A monoclonal antibody BRY805

A humanized monoclonal antibody against the human natural killer (NK) and T-lymphocyte cell checkpoint inhibitor killer cell lectin-like receptor subfamily C member 1 (NKG2A; natural killer group 2 A), with potential antineoplastic activity. Upon administration, anti-NKG2A monoclonal antibody BRY805 targets and binds to NKG2A, thereby preventing the binding of NKG2A to its ligand human leukocyte antigen-E (HLA-E), which is overexpressed on tumor cells. This blocks the HLA-E-mediated inhibition of NKG2A-positive infiltrating NK and cytotoxic T lymphocytes (CTLs) and induces a NK and CTL-mediated immune response against cancer cells leading to their destruction. Human NKG2A, an inhibitory cell surface receptor covalently bound to CD94, is expressed by NK cells and CTLs. Stimulation of the CD94/NKG2A complex inhibits the cytotoxic activity of these cells. HLA-E, a nonclassical HLA class Ib molecule, is often overexpressed on tumor cells and is associated with poor prognosis.
Code name:BRY 805
BRY-805
BRY805
Search NCI's Drug Dictionary